NCT06769412

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 550,000 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice. This study will also use clinical record review to confirm cases of RV first identified using International Classification of Diseases, tenth revision, Clinical Modification (ICD-10-CM) codes and to identify RV with occlusion.

Detailed description

This study is purely descriptive using secondary data from the Verana Health Retinal Outcomes module sourced from the American Academy of Ophthalmology's Intelligent Research in Sight (IRIS®) Registry

Conditions

• Retinal Vasculitis

Interventions

Type	Name	Description
DRUG	aflibercept 2 mg	No study-specific investigations for this descriptive observational study

Timeline

• Start date: 2025-07-01
• Primary completion: 2025-08-15
• Completion: 2025-09-01
• First posted: 2025-01-10
• Last updated: 2025-10-29

Locations

1 site across 1 country: United States